Can “Cold” Tumors be Converted to “Hot”?
Research By: Vishnu Modur, PhD | Kakajan Komurov, PhD
Post Date: November 5, 2019 | Publish Date: Sept. 6, 2019
Converting immunologically “cold” tumors into “hot” ones that can be more effectively treated is a burgeoning field in cancer research.
In a recent paper published in Oncoimmunology, researchers at Cincinnati Children’s report new details on how some tumors become “cold.” Their findings also suggest a possible way to make them “hot.”
Co-authors from Cincinnati Children’s include Vishnu Modur, PhD, and senior author Kakajan Komurov, PhD, (now with Pfizer).
The co-authors say that “artificial STING agonists and DNA methylation inhibitors (5-azacytidine), both of which are currently in clinical trials, may be attractive immediate candidates to test for the re-activation of the cGAS/STING pathway and re-expression of APP genes.”
|Original title:||Suppression of tumor antigen presentation during aneuploid tumor evolution contributes to immune evasion|
|Publish date:||Sept. 6, 2019|